Significant cardiovascular disease (New York Heart Association Class [NYHA] class II or greater); myocardial infarction within  month prior to randomization, unstable arrhythmias, unstable angina or a patient with a known left ventricular ejection fraction (LVEF) < %
Significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction within the previous  months, unstable arrhythmias, or unstable angina\r\n* Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < % must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
Known left ventricular ejection fraction (LVEF) < %. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF %?% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction (LVEF) < % must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate, to be eligible
Significant cardiovascular disease (New York Heart Associate [NYHA] class II or greater); myocardial infarction within  month prior to randomization, unstable arrhythmias, unstable angina or a patient with a known LVEF (left ventricular ejection fraction) < %
Significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction within  months prior to enrollment, unstable arrhythmias, or unstable angina; patients with known left ventricular ejection fraction (LVEF) < % will be excluded; patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < %, must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
Significant cardiovascular disease, such as:\r\n* New York Heart Association congestive heart failure class II or greater\r\n* Myocardial infarction, unstable angina or unstable arrhythmias within  months of enrollment\r\n* History of stroke or TIA within  months of enrollment\r\n* Other clinically significant arterial vascular disease within  months of enrollment (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis); prior history of adequately treated venous thromboembolism >  days prior to cycle  day  (CD) on stable dose of therapeutic anticoagulation is permitted\r\n* Subjects with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < % must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
Significant cardiovascular disease such as New York Heart Association (NYHA) class III or greater, myocardial infarction within the previous  months, unstable arrhythmias, unstable angina; patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < % must be on a stable regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist when appropriate
Clinically significant cardiovascular disease, including but not limited to, acute myocardial infarction within  months prior to enrollment, severe/unstable angina pectoris or coronary artery bypass grafting, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment or left ventricular ejection fraction (LVEF) < %;
Significant cardiovascular disease (New York Heart Association class II or greater); myocardial infarction within  months prior to enrollment, unstable arrhythmias, unstable angina or a patient with a known left ventricular ejection fraction (LVEF) < %
Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous  months, unstable arrhythmias, or unstable angina. Patient with known coronary artery disease, congestive heart failure not meeting the above criteria, or known left ventricular ejection fraction less than % must be on a stable medical regimen that is optimized in the opinion of the treating physician
Class II to IV heart failure as defined by the New York Heart Association functional classification system; patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction (LVEF) < % must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate, to be eligible
Significant cardiovascular disease such as New York Heart Association (NYHA) class II or greater, myocardial infarction within the previous  months of first study treatment, unstable arrhythmias, unstable angina; patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < % must be on a stable regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist when appropriate
Significant cardiovascular disease such New York Heart Association (NYHA) class III or greater, myocardial infarction within the previous  months, unstable arrhythmias, unstable angina, need for cardiac angioplasty or stenting, coronary artery by-pass graft surgery, symptomatic peripheral vascular disease; subjects with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < % must be on a stable regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist when appropriate
Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (class II or greater), myocardial infarction within  months prior to randomization, unstable arrhythmias, or unstable angina; patients with a known left ventricular ejection fraction (LVEF) < % will be excluded; patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < % must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate